Oxford University to Resume Coronavirus Vaccine Trial after Pause
The third phase trial of a possible coronavirus vaccine, developed by Oxford University and AstraZeneca, will resume after a pause.
The UK pharmaceutical company AstraZeneca on Saturday issuing a press release confirmed about the trial, according to a BBC report.
The trial announcement came after UK’s Medicines Health Regulatory Authority approved the vaccine as “safe” after a review.
On Tuesday, AstraZeneca postponed its trial after a UK national who took the coronavirus vaccine in a trial fell ill.
Health Secretary Matt Hancock welcomed the news that the trials would resume, BBC reports.
He added, “This pause shows we will always put safety first. We will back our scientists to deliver an effective vaccine as soon as safely possible.”
US, UK, Brazil and South Africa allowed to conduct the final trial of Oxford University vaccine on their 30,000 people. Meanwhile, AstraZeneca postponed its trial on last Tuesday.
The AstraZeneca vaccines are also at the top of the global rankings in competition for Covid-19 vaccines.
To Read Our Exclusive Content, Sign up Now.